These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1510 related articles for article (PubMed ID: 33738806)
1. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Chouaki Benmansour N; Carvelli J; Vivier E Eur J Immunol; 2021 Jul; 51(7):1652-1659. PubMed ID: 33738806 [TBL] [Abstract][Full Text] [Related]
2. [Involvement of the complement cascade in severe forms of COVID-19]. Chouaki Benmansour N; Carvelli J; Vivier É Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019 [TBL] [Abstract][Full Text] [Related]
3. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Carvelli J; Demaria O; Vély F; Batista L; Chouaki Benmansour N; Fares J; Carpentier S; Thibult ML; Morel A; Remark R; André P; Represa A; Piperoglou C; ; ; Cordier PY; Le Dault E; Guervilly C; Simeone P; Gainnier M; Morel Y; Ebbo M; Schleinitz N; Vivier E Nature; 2020 Dec; 588(7836):146-150. PubMed ID: 32726800 [TBL] [Abstract][Full Text] [Related]
4. A double edged-sword - The Complement System during SARS-CoV-2 infection. Santiesteban-Lores LE; Amamura TA; da Silva TF; Midon LM; Carneiro MC; Isaac L; Bavia L Life Sci; 2021 May; 272():119245. PubMed ID: 33609539 [TBL] [Abstract][Full Text] [Related]
5. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Jiang Y; Zhao G; Song N; Li P; Chen Y; Guo Y; Li J; Du L; Jiang S; Guo R; Sun S; Zhou Y Emerg Microbes Infect; 2018 Apr; 7(1):77. PubMed ID: 29691378 [TBL] [Abstract][Full Text] [Related]
7. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions. Root-Bernstein R Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738 [TBL] [Abstract][Full Text] [Related]
8. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. Kozma GT; Mészáros T; Bakos T; Hennies M; Bencze D; Uzonyi B; Győrffy B; Cedrone E; Dobrovolskaia MA; Józsi M; Szebeni J Front Immunol; 2021; 12():642860. PubMed ID: 33995361 [TBL] [Abstract][Full Text] [Related]
9. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876 [TBL] [Abstract][Full Text] [Related]
11. Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. Kumar A; Prasoon P; Sekhawat PS; Pareek V; Faiq MA; Kumari C; Narayan RK; Kulandhasamy M; Kant K Int Rev Immunol; 2021; 40(1-2):54-71. PubMed ID: 33111578 [TBL] [Abstract][Full Text] [Related]
12. Mathematical Modeling of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Network with Cytokine Storm, Oxidative Stress, Thrombosis, Insulin Resistance, and Nitric Oxide Pathways. Sasidharakurup H; Kumar G; Nair B; Diwakar S OMICS; 2021 Dec; 25(12):770-781. PubMed ID: 34807729 [TBL] [Abstract][Full Text] [Related]
13. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. Hafezi B; Chan L; Knapp JP; Karimi N; Alizadeh K; Mehrani Y; Bridle BW; Karimi K Cells; 2021 Jul; 10(7):. PubMed ID: 34359931 [TBL] [Abstract][Full Text] [Related]
14. Immune dysregulation and system pathology in COVID-19. Jamal M; Bangash HI; Habiba M; Lei Y; Xie T; Sun J; Wei Z; Hong Z; Shao L; Zhang Q Virulence; 2021 Dec; 12(1):918-936. PubMed ID: 33757410 [TBL] [Abstract][Full Text] [Related]
15. The potential association between PARP14 and SARS-CoV-2 infection (COVID-19). Tauber AL; Schweiker SS; Levonis SM Future Med Chem; 2021 Mar; 13(6):587-592. PubMed ID: 33467912 [TBL] [Abstract][Full Text] [Related]
16. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. Pum A; Ennemoser M; Adage T; Kungl AJ Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33445810 [TBL] [Abstract][Full Text] [Related]
17. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Tan LY; Komarasamy TV; Rmt Balasubramaniam V Front Immunol; 2021; 12():742941. PubMed ID: 34659238 [TBL] [Abstract][Full Text] [Related]
18. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm. Gangemi S; Tonacci A Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545 [TBL] [Abstract][Full Text] [Related]
19. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P Front Immunol; 2021; 12():589095. PubMed ID: 33995341 [TBL] [Abstract][Full Text] [Related]
20. Immunopathogenesis and treatment of cytokine storm in COVID-19. Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]